Moderna begins trial of Omicron-specific COVID vaccine booster
New York: US drug maker Moderna has started trial of a Covid booster vaccine that specifically targets the Omicron variant, the company has announced.
This is after Pfizer began an Omicron-specific trial early this week. The company expect to have the shots ready by March.
Moderna, in a statement, said that the first participant in the phase two trial has already received a dose of the omicron-specific booster shot.
The company expects to enroll about 600 adult participants ages 18 and over split equally between two groups.
Participants in the first group will have previously received two-doses of Moderna's original vaccine, and participants in the second group will have previously received the two-dose vaccine and the currently authorised booster shot.
Participants in both groups will receive a single dose of the omicron specific booster.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.